OncoTargets and Therapy
Dovepress
open access to scientific and medical research
Original research
OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 18.206.13.133 on 04-Jun-2020
For personal use only.
Open access Full Text article
ESHAP chemotherapy is efficient in refractory/
relapsed primary central nervous system
lymphoma: report of four cases
rodica Ungur 1,2
adrian Tempescul 3
christian Berthou 3
cristina Bagacean 1,2
Doinel radeanu 1
adriana Muresan 1
Mihnea Zdrenghea 1,2
1
Department of hematology, iuliu
hatieganu University of Medicine
and Pharmacy cluj, 2Department of
hematology, ion chiricuta Oncology
institute, cluj-napoca, romania;
3
Department of clinical hematology,
institute of cancerology and
hematology, Brest Teaching hospital,
Brest, France
correspondence: Mihnea Zdrenghea
Department of hematology, ion
chiricuta Oncology institute, 73, 21
Decembrie Boulevard, 400124 clujnapoca, romania
Tel +40 264 431 605
Fax +40 264 598 606
email mzdrenghea@umfcluj.ro
Introduction
Although non-Hodgkin’s lymphoma is a frequent cancer worldwide, primary central
nervous system lymphoma (PCNSL) is a rare malignancy, with an incidence of less
than 0.5 per 100,000 persons-years in the Western world.1 In more than 90% of cases,
it has the histological features of a diffuse large B-cell lymphoma (DLBCL). Because
of its low incidence, high grade evidence from large studies is lacking, and current
management is based on reports on rather small cohorts. Evidence is even scarcer in
the relapsed/refractory setting. The current standard first-line treatment for PCNSL
consists of high-dose methotrexate (MTX) in combination with a variety of drugs and
consolidation whole-brain radiotherapy, the latter being progressively replaced by
chemotherapy.2 For patients relapsing after first-line treatment, intensive chemotherapy
with autologous stem cell support is a feasible and relatively safe salvage therapy.
For elderly patients, not able to withstand autografting, the second line of treatment
is more controversial.
ESHAP (etoposide, solumedrol, high-dose cytarabine, and platinum) chemotherapy
has been found to be an effective salvage regimen for nodal B-cell and Hodgkin’s
lymphomas and is accepted as an induction treatment before autografting. The regimen
includes drugs known to be able to penetrate the blood–brain barrier3 and used for the
treatment of cerebral tumors or metastases.
Here, we describe four cases of patients with PCNSL, either relapsed or refractory
to first-line treatment, in which the induction with ESHAP chemotherapy allowed the
achievement of a complete remission. Autologous stem cell transplantation under
2771
submit your manuscript | www.dovepress.com
OncoTargets and Therapy 2015:8 2771–2773
Dovepress
© 2015 Ungur et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on
how to request permission may be found at: http://www.dovepress.com/permissions.php
http://dx.doi.org/10.2147/OTT.S89358
Powered by TCPDF (www.tcpdf.org)
Abstract: Primary central nervous system non-Hodgkin’s lymphoma is a rare presentation,
almost always of diffuse large B-cell type. Although there is no consensus regarding therapy
for this condition, induction regimens are based on high-dose methotrexate and consolidation
whole-brain radiotherapy, or, more preferred recently, blood–brain barrier penetrating drugs such
as etoposide, cytarabine, and alkylating agents like temozolomide, ifosfamide, and lomustine.
We present here four cases of relapsed/refractory primary central nervous system lymphoma
treated with ESHAP (etoposide, solumedrol, high-dose cytarabine, and platinum) chemotherapy
to complete remission, with the eligible patients proceeding to autologous transplantation.
We want to draw attention to this interesting, relatively well tolerated, underused therapeutic
option, in a setting where treatment options are scarce and evidence-based recommendations
are lacking.
Keywords: cerebral lymphoma, PCNSL, refractory, relapsed, platinum
Dovepress
Ungur et al
OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 18.206.13.133 on 04-Jun-2020
For personal use only.
Table 1 Outcome after ESHAP therapy with and without autologous stem cell transplantation in four patients with relapsed/refractory
Pcnsl
Patient
Age
(years)
Initial
treatment
Status after
initial treatment
Localization at
relapse
Time to relapse
(months)
ESHAP
cycles to CR
Outcome after salvage
therapy
1
57
4MBVP +
3arac +ifo
2arac +VP16
Progressive
disease
left parietal
1
2
in cr, 30 months after
ascT
2
62
4MBVP +
3arac +ifo
2arac +VP16
complete
remission
left parietal
24
1
relapsed after 8 months,
deceased at 12 months
3
78
4MBVP +
3arac +ifo
2arac +VP16
Progressive
disease
suprapeduncular
1
1
Deceased after 8 months
(not lymphoma related)
4
70
4MBVP +
3arac +ifo
2arac +VP16
complete
remission
suprapeduncular
14
2
relapsed after 10 months,
deceased at 12 months
Abbreviations: eshaP, etoposide, solumedrol, high-dose cytarabine, and platinum; Pcnsl, primary central nervous system lymphoma; cr, complete remission; ascT,
autologous stem cell transplantation; MBVP, methotrexate, carmustine, etoposide, methyl prednisolone; ifo, ifosfamide.
optimal conditions for the younger patients was thus possible. For the two elder patients, consolidation therapy using
the same regimen was continued. The Institutional Review
Board does not require ethical approval for case reports. All
patients signed informed consent forms.
During a calendar year (2011), we identified four patients.
All were HIV negative and treated for PCNSL with standard
high-dose MTX therapy using the local protocol: induction
therapy consisting of four cycles of MBVP (MTX, carmustine,
etoposide, methyl prednisolone) followed by consolidation
with three cycles of ifosfamide plus cytarabine and two cycles
of cytarabine and etoposide (no radiotherapy), either refractory or relapsed within 2 years after completion of treatment.
Patients’ characteristics are presented in Table 1.
At relapse, the patients were given ESHAP chemotherapy every 21 days. Dose adjustment was made for the
elder patients, according to the local protocol requiring a
30% reduction of etoposide, cytarabine, and platinum doses
for patients with performance status .1. An evaluation by
computed topography (CT) scan or magnetic resonance
imaging (MRI) was performed on day 1 of each cycle of
chemotherapy. The patients received primary granulocyte
colony stimulating factor prophylaxis for neutropenia from
day 8. Tolerance of the treatment was good; only one patient
(the oldest) presented infectious events and required hospitalization. Complete remission of cerebral lesions was seen
in all the four patients, after the first or the second cycle of
chemotherapy. The two younger patients (below 65 years)
underwent stem cell mobilization and peripheral blood harvest after a third cycle of ESHAP chemotherapy. A maximum
of two apheresis sessions were required to obtain .3×106
2772
Powered by TCPDF (www.tcpdf.org)
submit your manuscript | www.dovepress.com
Dovepress
CD34+ cells/kg. The patients then proceeded to autologous
stem cell transplantation (standard BEAM conditioning).
Discussion
PCNSL is a rare disease, representing less than 2% of all the
cases of non-Hodgkin’s lymphoma. Its incidence increases
with age, with a median age of 60–70 years.4 Also, there has
been a surge in HIV-related PCNSL cases in the nineties,
receding during the last decade.1,5 The presentation differs
in terms of localization, dimension and number of tumors,
symptoms varying from an intermittent neurological dysfunction to rapid impairment of neurological or cognitive
functions. PCNSL most frequently presents as a DLBCL
with typical perivascular localization, differing from DLBCL
of other localization. Other histological subtypes of cerebral
lymphoma are very rare.6
It is now well established that the first-line treatment for
PCNSL is based on an association of high doses of MTX
with other drugs, with or without whole-brain radiotherapy.
For refractory or relapsed cases, several regimens have been
proposed. Treatment with temozolomide, topotecan, carboplatin, and cytarabine achieve response rates of 26%–37%.7
Autologous stem cell transplantation is an important therapeutic option in these patients, allowing for an increase in
overall survival.8
Cisplatin-based ESHAP chemotherapy has for a long time
demonstrated efficacy in refractory/relapsed patients with
DLBCL.9 Soussain et al proved in a cohort of 65 patients
with relapsed/refractory DLBCL (including 27 patients with
bone marrow or CNS involvement, but not PCNSL) that
ESHAP chemotherapy is effective, allowing for peripheral
OncoTargets and Therapy 2015:8
OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 18.206.13.133 on 04-Jun-2020
For personal use only.
Dovepress
stem cell harvest and autologous stem cell transplantation.10
It has also been proven that ESHAP chemotherapy could
be administrated in elderly patients without significant
toxicity.11 Platinum-based chemotherapy is also effective in
infant brain tumors.12
Use of ESHAP in PCNSL has been rarely reported,
most notably in a French retrospective study of 22 immunocompetent patients with relapsed/refractory disease, of
which five received rituximab (R)-ESHAP, two obtaining
a complete and one a partial remission. The rest received
dexamethasone, high dose aracytine, and cisplatin +/-R, to
an overall complete remission rate of 27%.13 In our patients,
the use of ESHAP chemotherapy resulted in rapid regression
of symptoms and disappearance of lesions observed in CT or
MRI scans. The treatment was well tolerated; the two younger
patients were stem cell mobilized, and then autologous stem
cell transplantation was performed in optimal conditions. The
two elderly patients continued with two additional cycles of
the same regimen as consolidation therapy.
We saw a remarkable effectiveness of ESHAP chemotherapy in our patients, previously treated with high doses of
MTX, cytarabine, etoposide, and corticosteroids. Although
this is a report of a small series of patients, we propose
ESHAP chemotherapy as an efficient and well-tolerated
salvage regimen, ideally followed by autologous stem cell
transplantation, in relapsed/refractory primary CNS lymphoma. Obviously, as with all PCNSL treatments, there is
a need for larger, prospective trials to yield higher grade
evidence allowing for stronger recommendations.
Acknowledgments
Dr R Ungur acknowledges support under the frame of
European Social Fund, Human Resources Development Operational Program 2007–2013, Project No.POSDRU/159/1.5/
S/138776, Drs Zdrenghea and Bagacean from Grant
CNCS-UEFISCDI, Project Number PN-II-RU-PD-20113-0277, and Dr Zdrenghea from Grant 1494/2014 from the
University of Medicine and Pharmacy Cluj. The sponsors had
OncoTargets and Therapy
eshaP in relapsed cerebral lymphoma
no involvement in the collection, analysis and interpretation
of data, in the writing of the manuscript, and in the decision
to submit the manuscript for publication.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age,
gender, and racial differences in incidence and survival in primary CNS
lymphoma. Br J Cancer. 2011;105(9):1414–1418.
2. Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. How I
treat CNS lymphomas. Blood. 2013;122(14):2318–2330.
3. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues
in central nervous system malignancy: a reality check. J Clin Oncol. 2007;
25(16):2295–2305.
4. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the
incidence of primary central nervous system non-Hodgkin lymphoma:
a surveillance, epidemiology, and end results analysis. Cancer. 2002;
95(7):1504–1510.
5. O’Neill BP, Decker PA, Tieu C, Cerhan JR. The changing incidence of
primary central nervous system lymphoma is driven primarily by the
changing incidence in young and middle-aged men and differs from
time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma.
Am J Hematol. 2013;88(12):997–1000.
6. Montesinos-Rongen M, Siebert R, Deckert M. Primary lymphoma of the
central nervous system: just DLBCL or not? Blood. 2009;113(1):7–10.
7. Sierra del Rio M, Rousseau A, Soussain C, Ricard D, Hoang-Xuan K.
Primary CNS lymphoma in immunocompetent patients. Oncologist.
2009;14(5):526–539.
8. Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy
followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle
Osseuse-Therapie Cellulaire. J Clin Oncol. 2008;26(15):2512–2518.
9. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP – an effective
chemotherapy regimen in refractory and relapsing lymphoma: a 4-year
follow-up study. J Clin Oncol. 1994;12(6):1169–1176.
10. Soussain C, Souleau B, Gabarre J, et al. Intensive chemotherapy with
hematopoietic cell transplantation after ESHAP therapy for relapsed or
refractory non-Hodgkin’s lymphoma. Results of a single-centre study
of 65 patients. Leuk Lymphoma. 1999;33(5–6):543–550.
11. Aviles A, Neri N, Huerta-Guzman J, de Jesus Nambo M. ESHAP versus
rituximab-ESHAP in frail patients with refractory diffuse large B-cell
lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10(2):125–128.
12. Fouladi M, Gururangan S, Moghrabi A, et al. Carboplatin-based primary
chemotherapy for infants and young children with CNS tumors. Cancer.
2009;115(14):3243–3253.
13. del Rio MS, Choquet S, Hoang-Xuan K, et al. Platine and cytarabinebased salvage treatment for primary central nervous system lymphoma.
J Neurooncol. 2011;105(2):409–414.
Dovepress
Publish your work in this journal
OncoTargets and Therapy is an international, peer-reviewed, open
access journal focusing on the pathological basis of all cancers, potential
targets for therapy and treatment protocols employed to improve the
management of cancer patients. The journal also focuses on the impact
of management programs and new therapeutic agents and protocols on
patient perspectives such as quality of life, adherence and satisfaction.
The manuscript management system is completely online and includes
a very quick and fair peer-review system, which is all easy to use. Visit
http://www.dovepress.com/testimonials.php to read real quotes from
published authors.
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal
OncoTargets and Therapy 2015:8
submit your manuscript | www.dovepress.com
Dovepress
Powered by TCPDF (www.tcpdf.org)
2773